CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) Files An 8-K Other Events

CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) Files An 8-K Other Events
Item 8.01 Other Events.

On October 29, 2019, CASI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an exclusive Distribution License Agreement with Pharmathen Global BV, a company established under the laws of the Netherlands, to which the Company obtained an exclusive license to develop and distribute Octreotide long acting injectable (LAI) microsphere in the People’s Republic of China.

The terms of the agreement include an upfront payment and future milestone payments. CASI will be responsible for the development, import drug registration and product approval in China. CASI has a 10-year non-royalty exclusive distribution period after the product launch at agreed supply costs for the first three years.

  


About CASI PHARMACEUTICALS, INC. (NASDAQ:CASI)

Story continues below

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

An ad to help with our costs